BACKGROUND: The interferon-free antiviral regimen, sofosbuvir (SOF) and simeprevir (SIM) without ribavirin has been reported to achieve high sustained virologic response (SVR) rates with few adverse effects when treating patients with hepatitis C genotype 1 (HCV GT1) infection. However, there is scarcity of safety and efficacy data in this regimen after liver transplantation (LT). AIM AND METHODS: We aim to report the safety, tolerability and efficacy of SOF + SIM to treat LT recipients with recurrent HCV GT1 in a multicenter cohort study. RESULTS: Eighty-one patients with HCV GT1 met criteria to be considered for treatment. Sixty-seven patients received SOF + SIM following LT to date: 69% male, 39% with HCV RNA >6 000 000 IU/mL, 22% advanced hepatic fibrosis (stage 3-4), 6% cholestatic recurrence. Fifty-eight percent previously failed or did not tolerate interferon-based treatments. Mean time from LT to treatment was 6.1 ± 5.2 yr. All patients had estimated GFR >30 mL/min. Tacrolimus was primary immunosuppression in 84% of patients and minimal immunosuppression dose adjustments were required during treatment. In intention-to-treat analysis, 90% achieved end-of-treatment virologic response and 88% achieved SVR. CONCLUSIONS: Sofosbuvir + SIM combination therapy without ribavirin is well tolerated and results in high virologic response rates in recurrent HCV GT1 infection after liver transplantation.
BACKGROUND: The interferon-free antiviral regimen, sofosbuvir (SOF) and simeprevir (SIM) without ribavirin has been reported to achieve high sustained virologic response (SVR) rates with few adverse effects when treating patients with hepatitis C genotype 1 (HCV GT1) infection. However, there is scarcity of safety and efficacy data in this regimen after liver transplantation (LT). AIM AND METHODS: We aim to report the safety, tolerability and efficacy of SOF + SIM to treat LT recipients with recurrent HCV GT1 in a multicenter cohort study. RESULTS: Eighty-one patients with HCV GT1 met criteria to be considered for treatment. Sixty-seven patients received SOF + SIM following LT to date: 69% male, 39% with HCV RNA >6 000 000 IU/mL, 22% advanced hepatic fibrosis (stage 3-4), 6% cholestatic recurrence. Fifty-eight percent previously failed or did not tolerate interferon-based treatments. Mean time from LT to treatment was 6.1 ± 5.2 yr. All patients had estimated GFR >30 mL/min. Tacrolimus was primary immunosuppression in 84% of patients and minimal immunosuppression dose adjustments were required during treatment. In intention-to-treat analysis, 90% achieved end-of-treatment virologic response and 88% achieved SVR. CONCLUSIONS:Sofosbuvir + SIM combination therapy without ribavirin is well tolerated and results in high virologic response rates in recurrent HCV GT1infection after liver transplantation.
Authors: Sammy Saab; Justin Rheem; Melissa A Jimenez; Tiffany M Fong; Michelle H Mai; Caterina A Kachadoorian; Negin L Esmailzadeh; Sherona N Bau; Susan Kang; Samantha D Ramirez; Jonathan Grotts; Gina Choi; Francisco A Durazo; Mohammed M El-Kabany; Steven-Huy B Han; Ronald W Busuttil Journal: J Clin Transl Hepatol Date: 2017-05-14
Authors: Kian Bichoupan; Neeta Tandon; James F Crismale; Joshua Hartman; David Del Bello; Neal Patel; Sweta Chekuri; Alyson Harty; Michel Ng; Keith M Sigel; Meena B Bansal; Priya Grewal; Charissa Y Chang; Jennifer Leong; Gene Y Im; Lawrence U Liu; Joseph A Odin; Nancy Bach; Scott L Friedman; Thomas D Schiano; Ponni V Perumalswami; Douglas T Dieterich; Andrea D Branch Journal: World J Virol Date: 2017-11-12
Authors: Chiranjeevi Gadiparthi; George Cholankeril; Brandon J Perumpail; Eric R Yoo; Sanjaya K Satapathy; Satheesh Nair; Aijaz Ahmed Journal: World J Gastroenterol Date: 2018-01-21 Impact factor: 5.742